ERBB2 and non-small cell lung carcinoma: According to these data, trastuzumab-deruxtecan received “breakthrough therapy designation” from the FDA for the treatment of patients with metastatic NSCLC whose tumors have a HER2 mutation and with disease progression on or after platinum-based therapy.